Loading...
XSHG600351
Market cap617mUSD
Dec 25, Last price  
6.20CNY
1D
1.46%
1Q
13.61%
Jan 2017
-36.64%
Name

Yabao Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHG:600351 chart
P/E
22.37
P/S
1.53
EPS
0.28
Div Yield, %
1.15%
Shrs. gr., 5y
-0.55%
Rev. gr., 5y
-0.06%
Revenues
2.91b
+7.05%
596,803,472685,782,785741,299,852986,054,9751,254,651,5871,488,266,4311,181,821,8531,662,746,2841,266,573,1811,624,882,7811,889,657,4292,065,627,0721,806,110,1702,558,514,6212,918,099,2193,041,915,8982,602,423,1062,763,962,4812,718,134,7852,909,765,255
Net income
200m
+90.71%
31,250,98224,360,92421,822,21045,059,57785,455,888129,294,105144,301,943186,430,628112,287,473118,195,518170,121,894222,090,41022,521,863200,206,379273,335,26710,798,573107,369,054187,089,423104,655,073199,585,789
CFO
498m
+8.06%
79,725,96726,396,59311,590,939105,685,653102,899,172368,564,04418,565,50940,726,841056,801,873178,626,984143,466,388155,954,179161,726,197426,601,444425,169,570380,960,275437,503,470460,462,582497,553,579
Dividend
May 30, 20240.15 CNY/sh
Earnings
May 16, 2025

Profile

Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, APIs, and pharmaceutical packaging materials in China and internationally. The company provides products for pediatrics, female healthcare, cardiovascular, big health, and elderly chronic diseases under the Diarrago, Baiyu, and Yabao brands. It also offers plastic bottles and cartons. The company provides its products in the form of injections, tablets, capsules, granules, pills, patches, freeze-dried powders, mixtures, suppositories, and solutions. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Yuncheng, China.
URL
http://www.yabao.com.cn/
IPO date
Sep 26, 2002
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
2,909,765
7.05%
2,718,135
-1.66%
2,763,962
6.21%
Cost of revenue
2,380,797
2,280,859
2,334,714
Unusual Expense (Income)
NOPBT
528,968
437,276
429,248
NOPBT Margin
18.18%
16.09%
15.53%
Operating Taxes
39,068
21,043
17,830
Tax Rate
7.39%
4.81%
4.15%
NOPAT
489,900
416,233
411,418
Net income
199,586
90.71%
104,655
-44.06%
187,089
74.25%
Dividends
(51,263)
(61,600)
(38,500)
Dividend yield
0.97%
1.36%
0.55%
Proceeds from repurchase of equity
(150,447)
BB yield
2.86%
Debt
Debt current
202,220
434,548
507,226
Long-term debt
6,738
12,206
40,034
Deferred revenue
43,525
47,989
46,100
Other long-term liabilities
18,716
18,716
18,716
Net debt
(786,401)
(611,454)
(291,276)
Cash flow
Cash from operating activities
497,554
460,463
437,503
CAPEX
(99,855)
Cash from investing activities
(127,372)
Cash from financing activities
(446,753)
FCF
673,946
635,673
608,464
Balance
Cash
617,643
668,503
477,049
Long term investments
377,716
389,703
361,487
Excess cash
849,871
922,300
700,338
Stockholders' equity
1,949,092
2,055,046
2,011,988
Invested Capital
2,411,266
2,552,797
2,849,624
ROIC
19.74%
15.41%
13.99%
ROCE
16.17%
12.55%
12.05%
EV
Common stock shares outstanding
763,234
770,000
770,000
Price
6.90
17.35%
5.88
-35.24%
9.08
82.33%
Market cap
5,266,317
16.32%
4,527,600
-35.24%
6,991,600
82.33%
EV
4,497,034
3,952,711
6,736,940
EBITDA
688,660
601,104
600,306
EV/EBITDA
6.53
6.58
11.22
Interest
12,298
18,768
22,607
Interest/NOPBT
2.32%
4.29%
5.27%